As described before, these patients have comorbidities like diabetes and hypertension and in this context hyperglycemia and hypercolesterolemia, which are PI3K inhibitors common AEs [24] or proteinuria and hypertension that are VEGF inhibitors common AEs could become unacceptable toxicities [96]. This evidence concerns the gene VEGFA and diabetes mellitus.